Surrozen IND Cleared for SZN-8141; Trials Funded
Surrozen announced FDA clearance of its Investigational New Drug (IND) application for SZN-8141. The company expects a $95.1 million second closing to fund upcoming trials.
Surrozen announced FDA clearance of its Investigational New Drug (IND) application for SZN-8141. The company expects a $95.1 million second closing to fund upcoming trials.